Elevance Health Inc. (ELV) shares rose 4.9% to $416.54 as of September 11, 2026, a moderate gain from the prior close of $396.90. BestStocks flagged the session as a major change for ELV. Below, we break down what changed for ELV, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
ELV climbed 4.9% to $416.54
ELV rose 4.9% in its latest session, moving from $396.90 to $416.54.
ValuationMedium confidence
Rel. volume
1.3×
Normal
Vs peers
—
No comparable peers
Market cap
$90.3B
New York Stock Exchange
Analyst target
$444
+6.6% vs price
Price chart
Aug 11 – Sep 11
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Elevance Health Inc. investors
For Elevance Health Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 4.9% session move; Elevance Health Inc. (ELV) moved +2.93% from $382.23 to $393.44 on 2026-07-21. Weighing against that: Elevance Health reported Q2 2026 earnings before market open showing a sharp 30% year-over-year earnings decline to ~$6.18 per share, driven by surging medical costs and worsening medical loss ratios (Established source, uk.investing.com); New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $444.06, implying +6.6% upside from $416.54. BestStocks rates the overall signal quality medium (61/100). With earnings roughly 40 days out, the next report is the most likely near-term test of the move.
ELV price reaction
ELV last traded at $416.54, up $19.64 (+4.95%) from the previous close of $396.90. The session traded on 1.3× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $390.24 and $416.54, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Elevance Health Inc. (ELV)
The consensus analyst price target on Elevance Health Inc. (ELV) is $444.06, 6.6% above the recent $416.54. Over the past 90 days analysts logged 0 upgrades, 12 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ELV line up.
▲ The bullish case
+Wall Street's consensus price target of $444.06 implies +6.6% upside from $416.54.
+The Street's most bullish target is $498.00 (+19.6%).
+Positive 4.9% session move.
+Elevance Health Inc. (ELV) moved +2.93% from $382.23 to $393.44 on 2026-07-21.
+ELV moved +2.62% from $408.17 to $418.85 on 2026-07-07.
▼ The bearish case
−The most bearish analyst target is $391.00 (-6.1%).
−Elevance Health reported Q2 2026 earnings before market open showing a sharp 30% year-over-year earnings decline to ~$6.18 per share, driven by surging medical costs and worsening medical loss ratios (Established source, uk.investing.com).
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 11, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Elevance Health shares rose 2.04% to $414.13 as part of a broader defensive sector rotation into healthcare stocks amid macroeconomic volatility, according to web sources. The move builds on positive momentum from the company's strong Q2 results and full-year adjusted EPS guidance of at least $27, with an upcoming $1.72 quarterly dividend (ex-date September 10) providing additional support. Volume of 224,020 shares remained below average at 0.64x the expected level 150 minutes into the session.
Elevance Health rose 2.75% to $403.35, supported by institutional confidence following Q2 earnings that beat revenue estimates at $49.83 billion and prompted raised full-year guidance, per Yahoo Finance and WSJ sources. Analyst backing—including Bernstein's Buy rating with a $488 price target—and an approaching $1.72 per-share dividend ex-date (September 10, 2026) are reinforcing positive sentiment despite earlier post-earnings Medicaid spending concerns.
Elevance Health rose 2.15% to $407.45 as part of a broader investor rotation into health insurance and managed care following stabilization after Q2 earnings, supported by Wall Street's "Moderate Buy" consensus viewing earlier cost pressures as a potential trough with a path to margin recovery (Yahoo Finance, Investors.com). Sector sentiment has shifted toward healthcare stability as investors weigh shifting medical cost trends across the industry.
Elevance Health rose 2.67% to $400.67, driven by sustained positive sentiment following its Q2 earnings beat and raised 2026 outlook, combined with recent institutional buying interest and confidence in its value-based care and connected cancer care initiatives (per web synthesis corroborated by MarketWatch and Yahoo Finance). Volume of 461,483 shares ran below average at 0.56x expected for this stage of the session.
Material / Earnings2026-08-12+2.2%
Elevance Health Inc. (ELV) moved +3.15% from $386.94 to $399.14 on 2026-08-12. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting the move was not driven by unusual trading activity.
Material / Earnings2026-08-05+3.5%
Elevance Health Inc. (ELV) moved +4.28% from $375.20 to $391.24 on 2026-08-05. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Material / Earnings2026-07-29-2.5%
Elevance Health Inc. (ELV) moved -2.67% from $386.28 to $375.98 on 2026-07-29. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, suggesting modest institutional activity.
Material / Earnings2026-07-28+1.9%
Elevance Health Inc. (ELV) moved +3.00% from $374.51 to $385.73 on July 28, 2026. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred on modestly elevated volume (1.5x the 5-day average).
In-depth ELV event analyses
Permanent, dated analyses of ELV's most significant sessions.
ELV rose 4.9% to $416.54. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did ELV stock rise?
ELV gained 4.95% ($19.64) versus the prior close of $396.90, last trading at $416.54 on 1.3× average volume.
When is Elevance Health Inc.'s next earnings date?
ELV's next earnings report is estimated for 2026-10-21 — about 40 days away.
What is the analyst price target for ELV?
The consensus analyst price target for ELV is $444.06, about 6.6% above the current $416.54. Over the past 90 days, analysts recorded 0 upgrades, 12 maintains, and 0 downgrades.
How BestStocks tracks ELV
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared ELV-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for ELV, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 11, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
